AbbVie's beat fueled by demand for Humira, Hep C drugs
(Reuters) - AbbVie Inc reported a better-than-expected quarterly profit on Thursday, driven by higher sales of its rheumatoid arthritis treatment Humira and its Hepatitis C drugs, leading the company to raise its full-year earnings forecast.
from Reuters: Health News https://reut.rs/2JqzjQf
http://bit.ly/2zwRqiM
April 26, 2018
|
Labels:
health,
Reuters: Health News
|
This entry was posted on April 26, 2018
and is filed under
health
,
Reuters: Health News
.
You can follow any responses to this entry through
the RSS 2.0 feed.
or trackback from your own site.